Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]
Hemodial IntABSTRACT Background Iron overload in chronic kidney disease contributes to oxidative injury. The role of iron chelators, standard in transfusion‐related overload, remains unclear in chronic kidney disease. Aim To evaluate the efficacy and safety of iron chelators in adults with chronic kidney disease.
Rajha HE +6 more
europepmc +2 more sources
Antibacterial and Angiogenic Poly(ionic liquid) Hydrogels
Gels, 2022 Wounds, particularly under low-hydration conditions, require more time to repair successfully. Therefore, there is an urgent need to develop wound dressings that can accelerate wound healing.
Chengju Sheng +5 more
doaj +1 more source
DEVELOPMENT OF AN ANALYTICAL METHOD FOR THE DETERMINATION OF LEAD BASED ON LOCAL SURFACE PLASMON RESONANCE OF SILVER NANOPARTICLES [PDF]
Química Nova, 2020 Lead is environmental pollutant that even in low trace is harmful for human health and wildlife. In this study we presented a colorimetric method for determination of Pb2+ in water by aggregation of silver nanoparticles capped citrate in the presence of ...
Hamed Azimi +4 more
doaj +1 more source
Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors
Haematologica, 2016 Iron overload due to hemochromatosis or chronic blood transfusions has been associated with the development of osteoporosis. However, the impact of changes in iron homeostasis on osteoblast functions and the underlying mechanisms are poorly defined ...
Ulrike Baschant +6 more
doaj +1 more source
Ferroptosis Suppression by the M<sup>6</sup>A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. [PDF]
Adv Sci (Weinh)IGF2BP1 promotes gemcitabine resistance in pancreatic cancer by stabilizing m6A‐modified FTH1 transcripts and protecting them in stress granules, thereby suppressing ferroptosis. Pharmacological inhibition of IGF2BP1 disrupts this protective pathway, restores ferroptotic sensitivity, and enhances gemcitabine efficacy in resistant tumors.
Zhu YQ +10 more
europepmc +2 more sources
Aluminum removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine [PDF]
, 1986 Aluminum removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine. Aluminum removal via peritoneal dialysis was evaluated after the administration of deferoxamine in patients treated with CAPD and CCPD.
Norris, Keith C. +4 more
core +1 more source
Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation [PDF]
, 1987 Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation. As intravenous administration of deferoxamine is difficult in home dialysis patients we set out to determine the efficacy of intramuscular (i.m.) and intraperitoneal (i.p.)
Hasbargen, James A. +6 more
core +1 more source
Journal of Cardiovascular Magnetic Resonance, 2008 Background In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur.
Pibiri Martina +9 more
doaj +1 more source
Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
Antibiotics, 2022 Despite the benefits of red blood cell (RBC) transfusion therapy, it can render patients vulnerable to iron overload. The excess iron deposits in various body tissues cause severe complications and organ damage such as cardiotoxicity and mold infections.
Jason Yamaki +4 more
doaj +1 more source
Neural Regeneration Research, 2017 Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown.
Jian Hao +10 more
doaj +1 more source